“third-rock-ventures” Archives

Entry Author Date Location
NinePoint, Under New Leadership, Bags $31M More For Imaging Tech 11/30/15 Boston
Idea Behind Warp Drive’s New Cancer Attack Was Hiding In Plain Sight 11/10/15 Boston
Ex-Blueprint Med CEO Resurfaces With $7.5M to Fight Genetic Blindness 11/09/15 Boston
Despite Sanofi’s Help, MyoKardia Prices IPO Below Expectations 10/29/15 San Francisco
Venture Veterans Frazier Commit New $262M Fund To Biopharma Bets 10/29/15 San Francisco
Cancer Vaccines Back in Vogue as VCs Put $102M Into Gritstone Oncology 10/20/15 San Francisco
East Coast Biotech Roundup: Zafgen, Decibel, Voyager & More 10/16/15 Boston
Decibel Therapeutics Secures $52,000,000 Series A Financing Round 10/16/15 Boston
Third Rock, SR One Put $52M Into Decibel to Battle Hearing Loss 10/15/15 Boston
Voyager Charts an IPO Course Amid Choppy Biotech Waters 10/11/15 Boston
Boston’s Life Science Disruptors 2015: The Photos 10/06/15 Boston
Five Takeaways From “Boston’s Life Science Disruptors” 10/02/15 Boston
East Coast Biotech Roundup: Forum, Neon, Sarepta, Accelerator & More 10/02/15 Boston
Neon Therapeutics Obtains $55,000,000 Series A Funding Round 10/02/15 Boston
With $55M, Neon Wants To Make the Cancer Vaccine “Problem” Personal 10/01/15 Boston
Amid Biotech Swoon, Third Rock’s MyoKardia Tees up IPO 09/28/15 San Francisco
Celgene Cozies up to Nurix With $150M Drug Development Deal 09/16/15 San Francisco
Hear the Synlogic Story at Boston’s Life Science Disruptors Sept. 30 09/14/15 Boston
East Coast Biotech Roundup: Biogen, Watson, Data Dumps & More 09/11/15 Boston
With $229M Deal, Amicus Gets a New Drug And Perhaps a Voucher 08/31/15 New York
Constellation Pharma Plots IPO Run As Genentech Passes on Buyout Deal 08/24/15 Boston
Global Blood Thera Nabs $120M IPO, Doubles Share Price On First Day 08/11/15 San Francisco
CRISPR Race Heats Up As Gates, Crossovers Put $120M Into Editas 08/10/15 Boston
“Boston’s Life Science Disruptors” to Share Their Stories on Sept. 30 07/23/15 Boston
FDA Grants Blueprint Go-Ahead for Kinase Inhibitor Trials 07/13/15 Boston
Tackling Sickle Cell, Global Blood Therapeutics Joins IPO Queue 07/08/15 San Francisco
Good Times Roll on for Biotech VCs As Clarus Bags New $500M Fund 06/09/15 Boston
Eleven Bio’s Shares Routed as Dry Eye Drug Flunks Phase 3 Test 05/18/15 Boston
Ex-AstraZeneca Exec to Lead Surface’s “Next-Gen” Immuno-Oncology Plan 05/07/15 Boston
With $46M Haul, MyoKardia Becomes Third Rock’s Latest IPO Prospect 04/30/15 San Francisco
Page 1 of 14 next page »